S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

First International Summit on Interventional Pharmacoeconomics

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Deborah Collyar: What's In It for Patients?

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Mark J. Ratain, MD, of the University of Chicago, talks about why ibrutinib—which can lead to cardiotoxicities—should be studied at a lower dose for patients with chronic lymphocytic leukemia. Data suggest a reduced dose may prevent dose interruption due to adverse events and may have a better therapeutic index.

Apr

Today In Oncology

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Related Videos

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Deborah Collyar: What's In It for Patients?

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Pausing vs Continuing BTK Inhibitors at Time of COVID 19 Vaccination in Patients With CLL

Neoantigen-Selected TILs Boost Response to Immunotherapy in Heavily Pretreated GI Cancers

Low-Dose vs Regular-Dose Apixaban for Prevention of VTE Recurrence in Patients With Cancer

FDA Approves Nivolumab Plus Ipilimumab for Unresectable or Metastatic HCC

Novel BTK and BCL2 Inhibitors Redefine CLL Treatment Across Front-Line and Relapsed Settings